Cited 4 times in
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성훈 | - |
dc.date.accessioned | 2020-12-01T17:57:59Z | - |
dc.date.available | 2020-12-01T17:57:59Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180539 | - |
dc.description.abstract | Objective: To evaluate the effectiveness and safety of the combination of pegylated liposomal doxorubicin with carboplatin (CD) compared with those of carboplatin and paclitaxel (CP) for platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer in a real-world setting in Korea. Methods: We enrolled relevant patients from 9 institutions. All patients received CD or CP as the second- or third-line chemotherapy in routine clinical practice during 2013-2018. The primary endpoints were progression-free survival (PFS) and toxicity. The secondary endpoint included the objective response rate (ORR). Results: Overall, 432 patients (224 and 208 in the CD and CP groups, respectively) were included. With a median follow-up of 18.9 months, the median PFS was not different between the groups (12.7 vs. 13.6 months; hazard ratio, 1.161; 95% confidence interval, 0.923-1.460; p=0.202). The ORR was 74.6% and 80.1% in the CD and CP group, respectively (p=0.556). Age and surgery at relapse were independent prognostic factors. More patients in the CD group significantly experienced a grade 3 to 4 hematologic toxicity and hand-foot syndrome (13.8% vs. 6.3%), whereas grade 2 or more alopecia (6.2% vs. 36.1%), peripheral neuropathy (4.4% vs. 11.4%), and allergic/hypersensitivity reaction (0.4% vs. 8.5%) developed more often in the CP group. Conclusions: The safety and effectiveness of chemotherapy with CD in a real-world setting were consistent with the results from a randomized controlled study. The different toxicity profiles between the 2 chemotherapy (CD and CP) regimens should be considered in the clinical practice. Trial registration: ClinicalTrials.gov Identifier: NCT03562533. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Soo Jin Park | - |
dc.contributor.googleauthor | Jihye Kim | - |
dc.contributor.googleauthor | Hee Seung Kim | - |
dc.contributor.googleauthor | Jeong Won Lee | - |
dc.contributor.googleauthor | Ha Kyun Chang | - |
dc.contributor.googleauthor | Keun Ho Lee | - |
dc.contributor.googleauthor | Dae Yeon Kim | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Suk Joon Chang | - |
dc.contributor.googleauthor | Seung Su Han | - |
dc.contributor.googleauthor | Sang Yoon Park | - |
dc.contributor.googleauthor | Seung Hyuk Shim | - |
dc.identifier.doi | 10.3802/jgo.2020.31.e15 | - |
dc.contributor.localId | A00595 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 31912673 | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Ovarian Cancer | - |
dc.subject.keyword | Platinum | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Recurrence | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | e15 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.31(2) : e15, 2020-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.